Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Handheld analyser for measuring lactate

EKF Diagnostics : 08 November, 2013  (New Product)
Medica 2013 will see the Lactate Scout+ plus from EKF Diagnostics for point of care handheld lactate analysis
Handheld analyser for measuring lactate


EKF Diagnostics will be premiering two novel diagnostic tests at Medica 2013 from the 20th to the 23rd November in Deusseldorf, Germany.



On Stand C70 in Hall 3, EKF will introduce an updated version of Lactate Scout+, a hand-held POC analyzer for the measurement of lactate. This third version of Lactate Scout+ features hematocrit compensation which uniquely ensures that results from the analyzer are highly accurate, particularly in subjects with high concentrations of hematocrit such as elite athletes and neonates.



A second feature of the upgraded analyzer is that Lactate Scout+ now provides the fastest results (10 seconds) from the smallest sample of capillary blood (0.2 µL) of any competing device.



The second test to be introduced by EKF at Medica is a new test kit for Soluble tumour Necrosis Factor receptor 1 (sTNFr1). sTNFr1 identifies diabetic patients at high risk of End Stage Renal Disease (ESRD), up to 10 years in advance. Based on a standard ELISA, the test detects circulating levels of sTNFr1 in just a few hours. Early diagnosis of ESRD leads to improved patient outcomes and reduced healthcare costs. The ELISA kit, which was developed in conjunction with the Joslin Diabetes Center in Boston, USA, is also available for sale.



EKF CEO, Julian Baines commented, “20 years after the onset of overt nephropathy, approximately 20% of diabetic patients will have progressed to ESRD. Our sTNFr1 assay will lead to improvements in the way patients are managed and reduce the burden on healthcare systems. We are confident that sTNFr1 will provide a step-change in the way ESRD is detected and managed and we are in the process of identifying accredited test labs in the USA to complement our work in Europe.”


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo